Study Details
Design, interventions, and primary outcomes
About This Study
Leptomeningeal metastases (LM) is a lethal complication of malignant tumors, characterized by tumor cell invasion and proliferation within the subarachnoid space. LM from HER2-negative breast cancer remains challenging to treat, with a median overall survival of only 3-6 months despite aggressive therapy. This open-label, uncontrolled Phase I/II clinical study aims to evaluate the safety, feasibility, and potential efficacy of Sacituzumab Govitecan in combination with intrathecal pemetrexed chemotherapy for LM from HER2-negative breast cancer, with the objective of identifying a more effective treatment strategy.
Design
Interventions / Regimen
- Drug: Sacituzumab Govitecan — Patients receive Sacituzumab Govitecan 10mg/kg by intravenous infusion on days 1 and 8. Treatment cycles are every 21 days.
- Drug: Pemetrexed — Intrathecal pemetrexed chemotherapy, administered via intracerebroventricular or lumbar puncture, consists of three phases: induction therapy (15 mg twice weekly for 2 weeks), consolidation therapy (once weekly for 4 consecutive weeks), and maintenance therapy (once monthly).
Primary Outcomes
- Maximal tolerated dose (From the beginning of the treatment until two months after the treatment.)
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2026-01-01
Completion: 2027-06-15
Sex: ALL
Volunteers: false
Enrollment: 34 (ESTIMATED)
- Zhenyu Pan (PRINCIPAL_INVESTIGATOR) - Huizhou Hospital of Guangzhou Medical University
- Drug: Sacituzumab Govitecan — Patients receive Sacituzumab Govitecan 10mg/kg by intravenous infusion on days 1 and 8. Treatment cycles are every 21 days.
- Drug: Pemetrexed — Intrathecal pemetrexed chemotherapy, administered via intracerebroventricular or lumbar puncture, consists of three phases: induction therapy (15 mg twice weekly for 2 weeks), consolidation therapy (once weekly for 4 consecutive weeks), and maintenance therapy (once monthly).